News
Adults with overweight or obesity plus prediabetes maintain most of their weight loss with tirzepatide at more than 3 years, ...
News Medical on MSN16d
3-year study of tirzepatide shows that most patients only gain 5% or less from their lowest or ‘nadir’ weightNote – this is an early press release from the European Congress on Obesity in Malaga, Spain, 11-14 May. Please credit the congress when using this research.* New research to be presented at this year ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results